INTRODUCTION
Cytochrome P450 17A (CYP17A) is an important target in prostate cancer given its central role in the production of tumor-derived and adrenal androgens. 1 Abiraterone acetate, a pro-drug of abiraterone, is a rationally designed, irreversible potent inhibitor of CYP17. 1 Abiraterone acetate results in the reduction of androgens and also cortisol, which activates a negative feedback loop resulting in compensatory elevated adrenocorticotropic hormone and mineralocorticoid excess. 1, 2 Abiraterone acetate has been developed with the coadministration of glucocorticoids, which reduces the risk of secondary mineralocorticoid excess. 3, 4 Abiraterone acetate has demonstrated improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) both after (COU-301) and before (COU-302) chemotherapy. 3, 4 In initial phase 1/2 trials, abiraterone acetate was tested without concomitant steroids. 2, 5 Although mineralocorticoid toxicity (MT) was common (55%-90% of patients), symptoms generally were well managed with eplerenone. 2, 5 In subsequent phase 2/3 trials, steroids (at a dose of 10 mg/day of prednisone in COU-301/COU-302) were mandated for all patients. 3, 4, 6, 7 Cancer February 15, 2019 More recently, the Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (LATITUDE) and Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trials demonstrated that abiraterone acetate increased OS among men with locally advanced or metastatic hormone-sensitive prostate cancer. 6, 7 The LATITUDE trial included patients with de novo highrisk metastatic disease, whereas the STAMPEDE trial had a more heterogeneous patient population, including men with nonmetastatic prostate cancer (prednisone equivalent of 5 mg/daily). 6, 7 Men treated with abiraterone acetate and corticosteroids at stages of disease earlier than metastatic CRPC had a longer duration of treatment with abiraterone acetate and corticosteroids and consequently longer exposure for potential side effects from both agents.
Glucocorticoids play a complex role in the management, treatment, and progression of prostate cancer. Historically, glucocorticoids have resulted in symptom palliation and occasional cancer responses in patients with advanced disease. 8 However, unexpected iatrogenic stimulation of prostate cancer growth has been observed. 9, 10 In addition, because glucocorticoids are being used earlier in the disease course, patients are at risk of the adverse events (AEs) associated with long-term use.
To study the profile of toxicities from abiraterone acetate without steroids, we performed a multicenter, phase 2 study and explored hormone levels as potential biomarkers for secondary MT.
MATERIALS AND METHODS

Patients
The current study was a phase 2, single-arm, open-label study of abiraterone acetate without glucocorticoids in patients with CRPC (ClinicalTrials.gov identifier NCT02025010). A total of 60 patients were enrolled between June 2014 and August 2016 at the Dana-Farber Cancer Institute in Boston, Massachusetts (40 patients), and the Memorial Sloan Kettering Cancer Center in New York City (20 patients). Eligible patients had CRPC based on Prostate Cancer Working Group (PCWG) 2 criteria. 11 Patients were not required to have radiologic metastases.
Patients had controlled blood pressure (<140/90 mm Hg while receiving ≤3 antihypertensive agents) and normal potassium without supplementation. Patients may have received prior hormonal therapies and up to 2 cytotoxic therapies. Prior androgen synthesis inhibitors were not allowed, with the exception of ketoconazole. Other eligibility criteria included an Eastern Cooperative Oncology Group performance status ≤2 and normal organ and bone marrow function. Patients were excluded if they required chronic corticosteroids. The study was conducted after institutional review board approval at each of the participating institutions in accordance with the principals outlined in the Declaration of Helsinki. All patients provided written informed consent.
Treatment
Patients received abiraterone acetate at a dose of 1000 mg/daily without glucocorticoids and were monitored for MT. Patients who developed hypertension (≥140/90 mm Hg on 3 determinations) were treated with antihypertensives and/or a mineralocorticoid antagonist (eplerenone was preferred, although spironolactone was allowed) (see Supporting Fig. 1 ). Hypokalemia was treated with potassium supplementation and/or a mineralocorticoid antagonist (see Supporting Fig. 2 ). Patients with persistent or severe hypertension or hypokalemia, as defined in Supporting Figures 1 and 2 , had treatment with prednisone initiated at a dose of 5 mg twice daily.
In patients not requiring prednisone for toxicity management, prednisone at a dose of 5 mg twice daily was added at the time of PSA progression, as defined by PCWG2 criteria, 11 and subsequent PSA response was evaluated. Safety laboratory values were checked every 2 weeks for the first 12 weeks and then every 4 weeks. PSA and imaging assessment occurred every 4 weeks and 12 weeks, respectively. Treatment was continued until radiographic progression, significant toxicity, or the patient and/or physician requested withdrawal.
Serum Hormone Levels
Hormones were measured at baseline, on day 1 of cycle 2, and at the time of treatment discontinuation. The Supporting Information details the methodology used for serum hormone determinations.
Statistical Analysis
The primary endpoint was the percentage of patients requiring prednisone to manage MT. The criteria for identifying an excessive number of patients requiring prednisone was based on the sequential probability test with an α of 0.10, β of 0.10, P o of 0.10, and P A of 0.25. Every time a participant was classified as having persistent or severe mineralocorticoid excess, the cumulative number of participants with persistent or severe mineralocorticoid excess was compared with the number of Cancer February 15, 2019 participants who were evaluable for toxicity and an associated cutoff value of evaluable participants. If the true underlying percentage of patients requiring prednisone was 10% (based on COU-301 grade 3-4 hypertension, hypokalemia, and edema of 1%-4%, 2%-3%, and <15-2%, respectively; and COU-302 any grade hypertension, hypokalemia, and edema of 10%-22%, 17%, and 28%-31%, respectively), then the probability of identifying excessive patients requiring prednisone was 0.082 whereas if the true underlying percentage was 25%, the probability was 0.907. 3, 4 If >12 events were observed in 60 patients, we would then reject the null hypothesis that persistent and severe mineralocorticoid excess could be managed without the addition of prednisone. Secondary objectives included toxicity, PSA and radiographic response, and time to PSA and radiographic progression. Correlative objectives included the assessment of baseline and changes in hormone levels and association with MT.
Radiographic response as defined by Response Evaluation Criteria In Solid Tumors (RECIST; version 1.1) was summarized with 95% confidence intervals (95% CIs) using an exact binomial test. Toxicity was summarized using Common Terminology Criteria for Adverse Events (version 4.0). PSA response and progression were defined by PCWG2 criteria. 11 Radiographic progression was defined using RECIST (version 1.1) for soft-tissue and visceral disease and PCWG2 for bone disease. 11, 12 Time to PSA progression and radiographic progression was summarized using the Kaplan-Meier method.
Hormone levels were summarized as the median and interquartile range (IQR). Associations between levels at baseline and any grade MT, grade 3 to 4 MT, and the initiation of prednisone therapy for toxicity management were summarized using the Wilcoxon rank sum test. Associations between changes in hormones between cycle 1 and cycle 2 and the development of any grade MT were summarized using the Wilcoxon rank sum test excluding patients who developed MT during cycle 1. Given the exploratory nature of this analysis, we did not correct for multiple hypotheses.
RESULTS
Baseline Characteristics
A total of 60 patients were enrolled, 58 of whom received at least 1 dose of abiraterone acetate ( Table 1 ). The median age of the patients was 68 years. Sixteen patients (27.6%) received prior chemotherapy, 6 patients (10.3%) received prior enzalutamide, and 4 patients (6.9%) received prior ketoconazole. The majority of patients had metastases (53 patients; 91.4%). Twenty-six patients (44.8%) were receiving at least 1 antihypertensive agent and no patient was receiving a mineralocorticoid antagonist at the time of study enrollment.
MT and Prednisone Initiation
AEs of MT of any grade occurred in approximately 66% of patients (38 patients): hypertension in 28 patients (48.3%), hypokalemia in 15 patients (25.9%), and edema in 11 patients (19.0%) ( Table 2 ). The median number of days from the initiation of abiraterone acetate to anygrade hypertension or hypokalemia was 56 days (range, 14-492 days) and 39 days (range, 17-534 days), respectively ( Fig. 1) . Grade 3 to 4 MT occurred in 21% of patients (12 patients): hypertension in 9 patients (15.5%) and hypokalemia in 4 patients (6.9%) (no grade ≥3 edema). Of the patients who developed hypertension, 42.9% (12 of 28 patients) had a prior history of hypertension and were receiving antihypertensives at baseline.
A total of 33 patients (56.9%) required the use of antihypertensives: 48.5% (16 patients) received 1 agent, 
PSA and Radiographic Progression
Twenty-eight patients (48.3%) experienced PSA progression at a median of 10.2 months (95% CI, 6.5-19.4 months). Of these individuals, 21 (36.2%) initiated treatment with prednisone for PSA progression. The median time to the initiation of prednisone for PSA progression was 6.4 months (IQR, 4.6-11.1 months). Of patients who initiated treatment with prednisone for PSA progression, 6 (28.6%) experienced a PSA decline (median decline of 20%), with 1 patient achieving a PSA decline of >50% (89% decline). In patients with some PSA decline after the addition of prednisone, the median time to radiographic progression was 11 months from the time prednisone was initiated. In patients without any PSA decline, the median time to radiographic progression was 11 months. Of the 53 patients with metastases, 17 (32.1%) experienced radiographic progression and the median time to radiographic progression was 22.1 months.
Serum Hormone Levels
There was an association noted between lower baseline androgens, including androstenedione (P = .04), androsterone (P = .01), dehydroepiandrosterone (DHEA) (P = .03), and 17-hydroxyprogesterone (P = .03), and the development of any grade of MT (38 patients) ( Table 3) . Baseline hormones did not correlate with grade 3 to 4 MT (12 patients) or the addition of prednisone for the Limb pain 6 (10.3%) 0 (0%) 0 (0%) 0 (0%) 6 (10.3%) Peripheral sensory neuropathy 4 (7%) 2 (3.4%) 0 (0%) 0 (0%) 6 (10.3%) Maculopapular rash 6 (10.3%) 0 (0%) 0 (0%) 0 (0%) 6 (10.3%)
One patient experienced grade 2 heart failure, which possibly was related to treatment. treatment of hypertension or hypokalemia (7 patients) (see Supporting Tables 1 and 2 ). Supporting Figure 3 denotes changes in hormones during the first cycle. More pronounced declines in cortisone were associated with MT (P=.01) (see Supporting Table 3 ).
DISCUSSION
The results of the current study demonstrated that the administration of abiraterone acetate without glucocorticoids was feasible, although approximately 21% of patients (12 patients) experienced grade 3 to 4 MT and approximately 66% (38 patients) experienced MT of any grade. In the majority of patients, toxicities were effectively abrogated with antihypertensives, potassium supplementation, and/ or mineralocorticoid antagonists. In total, 9 of 58 patients (15.5%) required prednisone for toxicity management.
Compared with phase 3 studies using abiraterone acetate with 10 mg of daily prednisone, the results of the current study demonstrated a higher rate of grade 3 to 4 MT. 3, 4, 6, 7 In the COU-301 and COU-302 trials, rates of grade 3 to 4 hypertension, hypokalemia, and edema were 1% to 4%, 2% to 3%, and <1% to 2%, respectively. 3, 4 However, in the LATITUDE and STAMPEDE studies, which used lower doses of corticosteroids, rates of grade 3 to 4 hypertension, hypokalemia, and edema were 5% to 20%, 1% to 11%, and 0.3% to 1%, respectively. 6, 7 In the current study, grade 3 to 4 hypertension, hypokalemia, and edema occurred in 15.5%, 6.7%, and 0%, respectively, of patients. The majority of cases of MT (71%) were observed within the first 3 months; however, a small subset of patients developed delayed toxicity after prolonged treatment (14% and 10% of Figure 2 . Waterfall plot of best prostate-specific antigen (PSA) response to therapy with abiraterone acetate alone. A total of 40 patients (69.0%) achieved a PSA reduction of ≥50%, 29 of whom did not receive prior chemotherapy, 39 of whom did not receive prior enzalutamide, and 38 of whom who did not receive prior ketoconazole, and 21 patients (36.2%) achieved a ≥90% reduction. Five patients (8.6%) did not experience any PSA decline. Each bar represents an individual patient. Patients marked with an asterisk did not have radiographic evidence of metastatic disease. patients, respectively, developed toxicity after 6 months and 9 months). These data highlight the need for the regular monitoring of blood pressure and electrolytes throughout treatment. Although we do not recommend the routine use of abiraterone acetate without steroids, the clinician considering abiraterone acetate without steroids due to specific patient concerns should weigh the risks described herein with the possible benefits of avoiding daily steroids. Consideration of abiraterone acetate without glucocorticoids requires an assessment of a patient's predisposing factors for MT, such as baseline hypertension, hypokalemia, or edema, and additional patient education regarding the potential for toxicity, coaching on home blood pressure monitoring, and close communication with the care team. Corticosteroids are used commonly in patients with prostate cancer, and corticosteroid-related AEs associated with low-dose corticosteroids (equivalent prednisone dose of 10 mg/day) include hyperglycemia, 13, 14 myopathy, 14 edema, 14 dyspnea, 14 and cataracts. 13 Men with prostate cancer may have an increased susceptibility to toxicity due to advanced age and concurrent androgen deprivation Cancer February 15, 2019 therapy. Prospective studies have demonstrated that androgen deprivation therapy can cause sarcopenia, increased fat mass, weight gain, increased cholesterol and triglycerides, insulin resistance, and loss of bone mineral density, 15 and these overlap with the effects of corticosteroids. We believe the results of the current study provide treating physicians and patients who are concerned about corticosteroid toxicities with an assessment of the incidence of MT when abiraterone acetate is used without steroids and an algorithm for the use of antihypertensives including eplerenone and/ or potassium replacement in lieu of steroids. In a planned exploratory analysis evaluating serum hormones, we observed a correlation between lower baseline hormones and changes in hormones after 1 month of treatment of MT. The identification of biomarkers for secondary mineralocorticoid excess toxicity could potentially select patients at risk of developing MT after therapy with abiraterone acetate alone. We found that lower baseline serum androgens and 17-hydroxyprogesterone were associated with the development of toxicity. In addition, a steep decline in cortisone after 1 month of treatment was associated with MT. We hypothesized that patients with lower baseline hormone levels may be primed for increased activation of the negative feedback loop stimulating a rise in adrenocorticotropic hormone and thus a higher risk of MT. The current analysis was exploratory, and was limited by the small sample size. We do not recommend the use of these hormone levels to guide patient treatment, although this hypothesis could be tested in future studies.
No prior treatment
The results of the current study did not directly compare the efficacy of abiraterone acetate with prednisone versus abiraterone acetate alone. Comparisons with historical controls are confounded by differences in patient populations and methods. The population of the current study was heterogeneous, and included patients with nonmetastatic disease (8.6%) and those pretreated with chemotherapy (27.6%) and ketoconazole (6.9%). Approximately 69% of all patients experienced a PSA decline of ≥50% from baseline and patients with metastatic disease (53 patients) were found to have a median time to radiographic progression of 22.1 months. These metrics are comparable to those of historic studies (38% in the COU-301 trial with a PSA decline of ≥50% and radiographic progression-free survival of 5.6 months and 62% in the COU-302 trial with a PSA decline of ≥50% and radiographic progression-free survival of 16.5 months), and we concluded that the efficacy of abiraterone acetate without the coadministration of steroids is not compromised. 3, 4 The steroid-containing control arms of several large phase 3 studies observed a PSA response in 5.5% to 28% of patients, thereby suggesting that steroids alone may have modest clinical activity in patients with CRPC. 16 In the current study, we evaluated the addition of prednisone in patients with PSA progression. Although declines in PSA were observed in 28.6% of patients, only 1 patient experienced a PSA decline of ≥50%. Earlier studies evaluated low-dose dexamethasone in patients who experienced PSA progression while receiving treatment with abiraterone acetate alone and demonstrated a PSA decline ≥50% in 3 of 15 patients (20%). 5 Glucocorticoids potentially can have dual functions in both response and resistance in patients with CRPC. Although it has been hypothesized that glucocorticoids can suppress androgen production further by preventing a rise in substrates of backdoor androgen synthesis, 1 other studies have demonstrated that glucocorticoids and the glucocorticoid receptor may mediate resistance through the activation of mutated androgen receptor in patients with CRPC. 10 In addition, emerging data have suggested that the glucocorticoid receptor is upregulated in some patients with CRPC, within the context of enzalutamide, stimulating androgen receptor target gene expression and promoting tumor growth. 9, 17 The effects of glucocorticoids are likely heterogeneous and to the best of our knowledge, the effect at the tumor cell level cannot be determined.
Based on the product label, abiraterone acetate should be prescribed with steroids. The results of the current study demonstrated that abiraterone acetate used without corticosteroids resulted in secondary mineralocorticoid excess toxicities in approximately 66% of patients and that all but 12% of individuals could be treated effectively with mineralocorticoid antagonists, antihypertensives, and/or potassium replacement. Single-agent abiraterone acetate with prompt use of these agents may be a consideration for patients at risk of developing toxicities from corticosteroids and with limited predisposing factors for MT, such as baseline hypertension, hypokalemia, or edema. Additional biomarker studies are warranted to identify those patients at high risk of MT.
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